[EN] INHIBITORS OF CREATINE TRANSPORT AND USES THEREOF<br/>[FR] INHIBITEURS DE TRANSPORT DE CRÉATINE ET LEURS UTILISATIONS
申请人:RGENIX INC
公开号:WO2016176636A1
公开(公告)日:2016-11-03
This invention relates to compounds that inhibit creatine transport and/or creatine kinase, pharmaceutical compositions including such compounds, and methods of utilizing such compounds and compositions for the treatment of cancer.
[EN] INHIBITORS OF CREATINE TRANSPORT AND USES THEREOF<br/>[FR] INHIBITEURS DE TRANSPORT DE LA CRÉATINE ET LEURS UTILISATIONS
申请人:RGENIX INC
公开号:WO2015168465A1
公开(公告)日:2015-11-05
This invention relates to compounds that inhibit creatine transport and/or creatine kinase, pharmaceutical compositions including such compounds, and methods of utilizing such compounds and compositions for the treatment of cancer.
An Unusual Conformation of α-Haloamides Due to Cooperative Binding with Zincated Porphyrins
作者:Marina Tanasova、Qifei Yang、Courtney C. Olmsted、Chrysoula Vasileiou、Xiaoyong Li、Mercy Anyika、Babak Borhan
DOI:10.1002/ejoc.200900089
日期:2009.9
with a zinc porphyrin leads to an unprecedented conformation for the determination of the absolute stereochemistry of α-haloamides (α-halocarboxylic acids derivatized with 1,4-phenylenediamine) through the use of exciton-coupled circular dichroism (ECCD). With the use of chiral lactams, whose rotomeric contributions are minimized, both ECCD and NMR spectroscopy demonstrate that the porphyrin favors binding
PROCESS FOR PREPARING HALOGENATED CYCLOPROPANE DERIVATIVES
申请人:DAIICHI PHARMACEUTICAL CO., LTD.
公开号:US20010051750A1
公开(公告)日:2001-12-13
A process for preparing compounds represented by the following general formula (I) wherein X represents chlorine atom or other and R represents alkoxy group, amino group or other, which comprises the step of allowing a compound represented by the formula: CH
2
═CXF react with a compound represented by the formula: N
2
CHCOR in the presence of a catalyst containing a metal atom such as a transition metal of group 8 together with chiral carboxylic-type or amide-type ligands to preferentially obtain a stereoisomer of the compound of the general formula (I) wherein the stereochemical configuration at the 1-position is S-configuration
1
active ingredients which is also the case for protoporphyrinogen oxidase (PPO) inhibitors, a class of highly effective herbicides in use for more than 50 years. Hence, it is essential to continuously discover and develop new herbicidal PPO inhibitors with enhanced intrinsic activity, an improved resistance profile, enhanced crop safety, favorable physicochemicalproperties, and a clean toxicological profile